Literature DB >> 12787858

Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia.

Axel Becker1, Brigitte Peters, Helmut Schroeder, Tobias Mann, Gerald Huether, Gisela Grecksch.   

Abstract

It was investigated whether subchronic application of 30 mg/kg ketamine (Ket) induces reliable changes in behaviour and parameters of dopaminergic, glutamatergic, and serotonergic neurotransmissions, which might be the basis of an animal model in schizophrenia research. To test this, rats were injected with 30 mg/kg ip Ket daily for five consecutive days. In response to the first Ket injection, there was a decrease in activity time representing an acute Ket effect. Following the fifth injection, there were no differences between Ket- and saline (sal)-injected control rats in activity time, which might be a tolerance reaction. The following experiments were performed 2 or 4 weeks after Ket treatment. There were no effects on anxiety in either vehicle or Ket-treated rats using either low or high illumination levels in the elevated plus-maze. In the social interaction test, both groups of rats spent comparable times in social contact. The percentage of nonaggressive behaviour was decreased in Ket-treated rats. Two weeks after completion of the treatment, there was no effect on prepulse inhibition (PPI). Four weeks after the final Ket injection, latent inhibition (LI) was disrupted. There was no difference in the animals' activity in reaction to apomorphine (Apo) administration. Ket-treated rats injected with 0.1 mg/kg MK-801 showed an enhancement in locomotor activity. Ket treatment leads to an increase in D2 receptor binding in the hippocampus and a decrease in glutamate receptor binding in the frontal cortex. The authors did not find any changes in D1 receptor binding. The density of dopamine transporters was increased in the striatum. The density of 5-HT transporters was increased in the striatum, the hippocampus, and the frontal cortex. The results suggest that subchronic treatment with subanaesthetic doses of Ket induce schizophrenia-related alterations, which might be a useful animal model in the study of this disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12787858     DOI: 10.1016/S0278-5846(03)00080-0

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  85 in total

1.  Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure.

Authors:  Samantha L Rushforth; Thomas Steckler; Mohammed Shoaib
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Methoxetamine affects brain processing involved in emotional response in rats.

Authors:  M T Zanda; P Fadda; S Antinori; M Di Chio; W Fratta; C Chiamulera; L Fattore
Journal:  Br J Pharmacol       Date:  2017-08-19       Impact factor: 8.739

Review 3.  Translational research in central nervous system drug discovery.

Authors:  Orest Hurko; John L Ryan
Journal:  NeuroRx       Date:  2005-10

4.  Serum level of vascular endothelial growth factor decreased in chronic ketamine abusers.

Authors:  Ni Fan; Minling Zhang; Ke Xu; Xiaoyin Ke; Yi Ding; Daping Wang; Yuping Liu; Yuping Ning; Xuefeng Deng; Hongbo He
Journal:  Drug Alcohol Depend       Date:  2015-05-08       Impact factor: 4.492

5.  Juvenile exposure to ketamine causes delayed emergence of EEG abnormalities during adulthood in mice.

Authors:  R E Featherstone; L R Nagy; C G Hahn; S J Siegel
Journal:  Drug Alcohol Depend       Date:  2013-09-27       Impact factor: 4.492

6.  Acute ketamine induces hippocampal synaptic depression and spatial memory impairment through dopamine D1/D5 receptors.

Authors:  Ting-Ting Duan; Ji-Wei Tan; Qiang Yuan; Jun Cao; Qi-Xin Zhou; Lin Xu
Journal:  Psychopharmacology (Berl)       Date:  2013-03-14       Impact factor: 4.530

7.  Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia.

Authors:  Axel Becker; Gisela Grecksch; Gerald Zernig; Elisabeth Ladstaetter; Christoph Hiemke; Ulrich Schmitt
Journal:  Psychopharmacology (Berl)       Date:  2008-09-23       Impact factor: 4.530

Review 8.  Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

9.  Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia?

Authors:  Mariana Bendlin Calzavara; Wladimir Agostini Medrano; Raquel Levin; Sonia Regina Kameda; Monica Levy Andersen; Sergio Tufik; Regina Helena Silva; Roberto Frussa-Filho; Vanessa Costhek Abílio
Journal:  Schizophr Bull       Date:  2008-02-16       Impact factor: 9.306

Review 10.  Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion.

Authors:  Christopher Barkus; Stephen B McHugh; Rolf Sprengel; Peter H Seeburg; J Nicholas P Rawlins; David M Bannerman
Journal:  Eur J Pharmacol       Date:  2009-10-15       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.